Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Trading Statement

23 Jan 2012 07:01

RNS Number : 9672V
Surgical Innovations Group PLC
23 January 2012
 



For immediate release

23 January 2012

 

 

Surgical Innovations Group plc

("SI" or "the Group")

Trading update

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery, is pleased to provide the following trading update.

 

During the year to 31 December 2011 the Group has traded in line with market expectations.

 

In difficult market conditions SI continued to trade according to plan in the second half of 2011, with a strong fourth quarter. The focus towards development of US opportunities is a major element of the company's strategy, particularly with the current challenges throughout the European market. Orders from the US have continued to grow as a result of strengthened routes to market complementing our Master Dealer's growing distribution network.

 

The Group has continued to see positive results from its investment program in product development; sales of the innovative PretzelFlex™ laparoscopic retractor have been encouraging following its launch in November. In addition, new handle technology with improved ergonomics for an OEM customer will soon be undergoing clinical evaluations in preparation for launch in the US market.

 

The concept and development teams have benefited from support from our Clinical Advisory Board, which has been strengthened by three new appointments this month from the fields of general surgery and arthroscopy. We have made advances with our arthroscopy project, and the Group is targeted to introduce a number of new pre-production products at an international arthroscopic clinical congress in the second half of 2012.

 

The senior management and finance team was strengthened following the appointment of Mike Thornton, formerly a partner at PricewaterhouseCoopers, as Financial Director of Surgical Innovations Limited in December. Mike, who reports directly to Graham Bowland and the Group Board, has already made a positive impact.

 

Graham Bowland, Chief Executive Officer, said: "SI has made progress in 2011, particularly in the US and in the development and launch of new products. The Group looks forward with confidence."

 

Preliminary results for the year to 31 December 2011 are expected to be released on 24 April 2012.

- Ends -

For further enquiries:

Surgical Innovations Group plcDoug Liversidge, ChairmanGraham Bowland, Chief Executive Officer +44 (0)113 230 7597

Seymour Pierce Limited

Freddy Crossley/ Sarah Jacobs Tel: +44 (0) 20 7107 8000

Corporate Broking

David Banks / Jacqui Briscoe www.seymourpierce.com

The Communications PortfolioAriane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

 

 

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets.

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

Over 140 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

The Group's patented products are sold through three main channels:

SI brand

Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia.

OEM and IP

The Group supplies large medical device companies on an OEM basis, collecting both sales and IP royalty fees. Clients include Teleflex Medical, Olympus, Gyrus and CareFusion.

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.

For more information, see www.sigroupplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGMGZMRZDGZZM
Date   Source Headline
27th Sep 20193:40 pmRNSExercise of Options, Issue of Equity and TVR
17th Sep 20197:00 amRNSHalf-year Report
3rd Sep 20197:00 amRNSNotice of Results
19th Jun 20194:03 pmRNSResult of AGM
19th Jun 20197:00 amRNSBoard and management structure changes
7th Jun 20197:00 amRNSTrading Update
6th Jun 20192:00 pmRNSHolding(s) in Company
29th May 20193:06 pmRNSExercise of Options, PDMR Shareholding & TVR
23rd May 201910:38 amRNSHolding(s) in Company
22nd May 201910:16 amRNSHolding(s) in Company
13th May 20196:25 pmRNSNotification of Major Interest in Shares
27th Mar 20197:00 amRNSGrant of Options
15th Mar 20194:27 pmRNSDirector/PDMR Shareholding
12th Mar 20197:00 amRNSFinal Results
28th Feb 20196:18 pmRNSExercise of Options & Total Voting Rights
28th Feb 20197:00 amRNSAppointment of CEO & changes in senior management
27th Feb 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUpdate on contingency planning for no-deal Brexit
14th Jan 20197:00 amRNSYear-end Trading Update
3rd Dec 20187:00 amRNSAppointment of Nominated Adviser and Broker
6th Nov 20187:00 amRNSSurgical robot technology UK distribution deal
16th Oct 201810:53 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSCE mark certification obtained for CELLIS range
11th Sep 201810:23 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSHalf-year Report
29th Aug 20187:00 amRNSCE mark validation indicated for CELLIS range
22nd Aug 20187:00 amRNSNotice of Results
26th Jun 20184:41 pmRNSResult of AGM
26th Jun 20187:00 amRNSAGM Statement
4th Jun 201811:34 amRNSHolding(s) in Company
25th May 20187:00 amRNSTrading Update
23rd Mar 20183:25 pmRNSDirector/PDMR Shareholding
13th Mar 20183:06 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
28th Feb 20187:00 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:01 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSYear-end trading update
21st Dec 201712:15 pmRNSIssue of Shares
15th Nov 201711:47 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSDirector/PDMR Shareholding
31st Oct 201710:58 amRNSDirector/PDMR Shareholding
31st Oct 20177:00 amRNSGrant of Options
30th Oct 20172:33 pmRNSIssue of Equity
10th Oct 20173:36 pmRNSIssue of Equity
26th Sep 201712:28 pmRNSIssue of Equity
22nd Sep 20178:55 amRNSHolding(s) in Company
13th Sep 20177:00 amRNSHalf-year Report
10th Aug 20177:00 amRNSNotice of Results
4th Aug 201712:32 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.